VERAXA Biotech (NASDAQ: VRXA), a company focused on developing novel cancer therapies, has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone follows the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on engineering the final therapeutic candidate by combining the antibody binders identified through the collaboration with its proprietary linker and conjugation technologies.
Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary antibody engineering, linker, and conjugation technologies. This positions VXA-222 as one of VERAXA's more advanced development programs, highlighting the company's ability to integrate external discoveries with its own innovative platforms. The advancement of VXA-222 is a significant step forward for VERAXA as it continues to build a diversified oncology pipeline targeting difficult-to-treat cancers.
In addition to the progress on VXA-222, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, securing VERAXA's innovative approaches for years to come.
The expansion of the patent portfolio is crucial for VERAXA as it seeks to establish a strong foothold in the competitive field of cancer therapeutics. By protecting its proprietary technologies, VERAXA can maintain a competitive edge and potentially generate revenue through licensing agreements. The patents cover a range of areas, including the BiTAC platform, which is a key focus for the company's future development.
VERAXA's pipeline includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats. These modalities are designed to address various mechanisms of action in cancer treatment, offering potential advantages over traditional therapies. The company's commitment to innovation is evident in its strategic partnerships and its focus on building a robust intellectual property estate.
The announcement of VXA-222's progression and the patent portfolio expansion comes at a time when the biotech industry is increasingly focused on next-generation antibody technologies. VERAXA's approach, which combines multiple proprietary technologies, could position it as a leader in this space. The company's ability to advance its programs and protect its innovations will be key to its success in bringing new treatments to patients.
Investors and stakeholders will be watching closely as VERAXA moves forward with VXA-222 and other pipeline candidates. The company's progress in the discovery phase and its strategic expansion of intellectual property demonstrate a commitment to long-term growth. With a diversified pipeline and a strong patent portfolio, VERAXA is well-positioned to make significant contributions to the field of oncology.
